Sight Sciences (SGHT) said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield "meaningful" cost savings based on the results of a budget impact analysis.
The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.
A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.